Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
90,438,636
-
Total 13F shares
-
22,072,299
-
Share change
-
-763,987
-
Total reported value
-
$630,570,267
-
Put/Call ratio
-
204%
-
Price per share
-
$28.57
-
Number of holders
-
149
-
Value change
-
-$52,611,712
-
Number of buys
-
62
-
Number of sells
-
88
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2018
As of 31 Dec 2018,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
149 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,072,299 shares.
The largest 10 holders included
Versant Venture Management, LLC, NEA Management Company, LLC, ARK Investment Management LLC, FARALLON CAPITAL MANAGEMENT LLC, Abingworth LLP, WADDELL & REED FINANCIAL INC, WELLINGTON MANAGEMENT GROUP LLP, CREDIT SUISSE AG/, FEDERATED INVESTORS INC /PA/, and BlackRock Inc..
This page lists
150
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.